Alloy Therapeutics Partners with Sanofi to Advance Innovative Therapeutics in the CNS Space
Shots:
- Alloy Therapeutics and Sanofi have entered into a target specific partnership to leverage Alloy's AntiClastic Antisense Platform for a CNS target
- Sanofi will utilize its neuroscience expertise to develop genetic medicines that cross the blood-brain barrier. It will pay up to $27.5M as upfront & near-term preclinical milestones as well as $400M as discovery, development & commercial milestones plus tiered royalties on resulting product sales
- Alloy’s AntiClastic Antisense platform enables RNA-level targeting of intracellular diseases, overcoming limitations in antisense therapeutic index
Ref: Alloy Therapeutics | Image: Alloy Therapeutics & Sanofi
Related News:- Pharmanovia Collaborates with Lindis Biotech to Commercialize Catumaxomab for Treating Malignant Ascites
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
